Verastem, Inc. (VSTM)
$10.23
Performance
- $10.19$11.02$10.23
0.39%
Downside
Day's Volatility :7.53%
Upside
7.17%
- $4.26$15.18$10.23
58.36%
Downside
52 Weeks Volatility :71.94%
Upside
32.61%
Returns
| Period | Verastem, Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 4.33% | -0.7% | 0.0% |
6 Months | 42.82% | 6.6% | 0.0% |
1 Year | 136.97% | 3.7% | -1.5% |
3 Years | 301.48% | 14.0% | -21.8% |
Highlights
Market Capitalization | 276.6M |
Book Value | $2.27 |
Earnings Per Share (EPS) | -3.96 |
PEG Ratio | -1.89 |
Wall Street Target Price | 28.79 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -47.03% |
Return On Equity TTM | -138.76% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 2.6M |
EBITDA | -92.0M |
Diluted Eps TTM | -3.96 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.76 |
EPS Estimate Next Year | -2.7 |
EPS Estimate Current Quarter | -0.62 |
EPS Estimate Next Quarter | -0.8 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 181.43%
Technicals Summary
Sell
Neutral
Buy
Verastem, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Verastem, Inc. | 2.07% | 42.82% | 136.97% | 301.48% | 399.54% |
 Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
 Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
 Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
 Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Verastem, Inc. | NA | NA | -1.89 | -3.76 | -1.39 | -0.47 | NA | 2.27 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Verastem, Inc. | Buy | $276.6M | 399.54% | NA | 0.0% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
Institutional Holdings
Viking Global Investors LP
9.71%Bvf Inc
6.66%Deerfield Management Co
6.08%Vivo Capital, LLC
6.08%Orbimed Advisors, LLC
6.05%Soleus Capital Management, L.P.
5.64%
Corporate Announcements
Verastem, Inc. Earnings
Verastem, Inc.’s price-to-earnings ratio stands at None
Read More
Company Information
verastem, inc. (nasdaq: vstm) is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. cancer stem cells are an underlying cause of tumor recurrence and metastasis. verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. for more information, please visit www.versatem.com
Organization | Verastem, Inc. |
Employees | 73 |
CEO | Mr. Daniel W. Paterson |
Industry | Health Technology |
